Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

79.68 USD +0.28 (+0.35%)
Streaming Delayed Price Updated: 1:47 PM EDT, Apr 19, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Biomarin Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
BioMarin Announces New and Updated Data at 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting Demonstrating Commitment to Understanding Achondroplasia and P
Normal Progression of Bone Age with Chronological Age Over 60 Months with Vosoritide for Children with Achondroplasia 
From PR Newswire
BioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 29,... 
From PR Newswire
BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society's Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide
Height Gain is Maintained in 2nd Year of Treatment 
From PR Newswire
BIOMARIN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into BioMarin... 
From Business Wire News Releases
BioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A
RMAT Designation Granted by FDA During Bleeding Disorders Awareness Month 
From PR Newswire
BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia
Topline data expected to be available in mid-2022 
From PR Newswire
BIOMARIN INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into BioMarin... 
From PR Newswire
BioMarin Announces Fourth Quarter and Record Full-year 2020 Financial Results and Corporate Updates
- Full-year 2020 Total Revenues Increased 9% to $1.86 billion 
From PR Newswire
BioMarin to Participate in Four Upcoming Virtual Investor Conferences
- 2021 SVB Leerink Global Healthcare Conference on February 26 at 11:20am ET 
From PR Newswire
BioMarin Appoints Former Goldman Sachs Partner and Life Sciences Executive, Maykin Ho, Ph.D. to Board of Directors
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former Goldman Sachs partner and executive in the life... 
From PR Newswire
BioMarin Earns Top Marks in Human Rights Campaign's 2021 Corporate Equality Index
- BioMarin earns a 100 score on the Human Rights Campaign Foundation's annual assessment of LGBTQ workplace equality 
From PR Newswire
BioMarin to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25 at 4:30pm ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February... 
From PR Newswire
NASDAQ:BMRN Long-Term Investor Notice: Investigation of Potential Wrongdoing at BioMarin Pharmaceutical Inc.
San Diego, CA -- (SBWIRE) -- 01/18/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of BioMarin Pharmaceutical Inc.. 
From SBWire - Latest Press Releases
BIOMARIN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into BioMarin... 
From Business Wire News Releases
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Long Term Investor Notice: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 01/14/2021 -- Certain directors of BioMarin Pharmaceutical Inc are under investigation over potential breaches of fiduciary duties. 
From SBWire - Latest Press Releases
BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set
- Significantly Reduced Mean Annualized Bleeding Rate by 84% (p-value <0.0001) Demonstrating Superiority to Factor VIII Prophylaxis, and Reduced Mean Annualized Factor VIII Infusion Rate by 99%... 
From PR Newswire
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
- Goldman Sachs 13th Annual Healthcare CEOs Unscripted Conference: A View from the Top on January 5 at 12:35pm ET 
From PR Newswire
BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study
Children Treated with Vosoritide Demonstrate Cumulative Height Gain of 3.52 cm at Year 2 Compared to Untreated Children 
From PR Newswire
Annual Changes to the Nasdaq-100 Index
From GlobeNewswire News Releases
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
- Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2 at 3:00pm ET 
From PR Newswire
BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: November 24, 2020
From GlobeNewswire News Releases
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against BioMarin Pharmaceutical Inc. 
From Business Wire News Releases
BIOMARIN 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Ph
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until November 24, 2020 to file lead plaintiff... 
From PR Newswire
DEADLINE ALERT for GTX, GTXMQ, BMRN, BTU, PT: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
From GlobeNewswire News Releases
BMRN FINAL DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds BioMarin Pharmaceutical Inc. Investors of Important Tuesday Deadline in Securities Class Action – BMRN
From GlobeNewswire News Releases
DEADLINE ALERT for WRTC, GLNG, GTX, GTXMQ, and BMRN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
From GlobeNewswire News Releases
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of BMRN, GTX and LRN
From ACCESSWIRE
BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN
ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until November 24, 2020 to file lead plaintiff applications in a securities class action lawsuit against... 
From Business Wire News Releases
BIOMARIN 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Ph
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until November 24, 2020 to file lead plaintiff... 
From Business Wire News Releases
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals Inc. (BMRN)
The Law Offices of Frank R. Cruz reminds investors of the upcoming November 24, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased BioMarin... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.